/
We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target…
The business is unprofitable at the operating level (-358.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 644.9% YoY with margins expanding 2026.8pp.
Negative free cash flow of -$303M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$93M
▲ +644.9% YoY
Net Income (TTM)
-$289M
▼ -30.3% YoY
Op. Margin
-285.91%
▲ +2026.8pp YoY
ROIC
-70.88%
▲ +0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$287M
▼ -32.5% YoY
Op. Cash Flow (TTM)
-$273M
▼ -37.5% YoY
Net Debt
-$149M
Net Cash Position
Cash & Equiv.
$229M
Continue Research